Clinical Trial Update: A Phase 2 Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis [Phase 2]

View source ↗

Summary

Deltanoid's oral vitamin D compound DP001 completed a Phase 2 study evaluating its effects in secondary hyperparathyroidism among patients on hemodialysis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Hyperparathyroidism

Drugs mentioned

• DP001

Snippet

Sponsor: Deltanoid Pharmaceuticals | Conditions: Hyperparathyroidism, Secondary, Kidney Failure, Chronic | Phase 2 | Status: COMPLETED